Grants Portfolio - Active Awards

AFTD-ADDF Accelerating Drug Discovery for FTD


TTBK1 inhibitors as new therapeutic approach for FTD and other related disorders

Ana Martinez, PhD | Ankar Pharmaceuticals 
May 2023

Robert Willliams

Selecting lead candidate REV-ERB agonist for the treatment of FTD

Robert Williams, PhD | Pelagos Pharmaceuticals
May 2023

Kenneth Kosik

Discovery of selective LRP1 inhibitors to prevent tau uptake and spread

Kenneth Kosik, MD  |  University of California Santa Barbara
December 2021

Wen-Hsuan Chang, PhD

Development of PIKFYVE antisense oligonucleotides (ASO) treatment for FTD

Wen-Hsuan Chang, PhD  |  AcuraStem Inc.
May 2021

Dieter Edbauer, MD

Preclinical efficacy study for antibody therapy in C9orf72 FTD/ALS mice

Dieter Edbauer, MD  |  German Center for Neurodegenerative Diseases
December 2019

Ted Huey

Low-dose lithium for the treatment of behavioral symptoms in FTD

Edward Huey, MD  |  Brown University

AFTD-ADDF Diagnostics Accelerator

Judith Steen, PhD-01

Judith Steen, PhD  |  Harvard Medical School
September 2020
$572,678 USD

Rodney Pearlman, PhD-01

Rodney Pearlman, PhD  |  Bluefield Project to Cure FTD
October 2019
$1,200,000 USD

FTD Biomarkers Initiative

Headshots / Lashley_Sander

Mapping neuroinflammation in frontotemporal lobar degeneration – development of a surrogate marker for early diagnosis and disease progression

Tammaryn Lashley, MD, PhD and Kerstin Sander MD  |  University College London
October 2022

Headshots / Lashley_Sander

Accelerating tau PET imaging through head to head comparison of novel radiotracers

Tammaryn Lashley, MD, PhD and Kerstin Sander MD  |  University College London
December 2018

Headshots / Dr. Anthony Fitzpatrick

Cryo-electron microscopy of brain-derived TDP-43 filaments to rationally design PET ligands for FTD

Anthony Fitzpatrick, PhD  |  Columbia University Medical Center
March 2019

Headshots / Leonard Petrucelli, PhD-1

Assessing poly(GP) proteins as clinical and pharmacodynamic biomarkers of C9ORF72-associated FTD

Leonard Petrucelli, PhD  |  Mayo Clinic Jacksonville
October 2019

Headshots / Magdalini Polymenidou

Targeting structural alterations of TDP-43 and other proteins to develop biomarkers for FTLD subtypes

Magdalini Polymenidou, PhD  |  University of Zurich, Switzerland
September 2019

Digital Assessment Tools for FTD and ALS


Harmonizing remote smartphone assessments of cognition, behavior, and motor functioning across the spectrum of FTD and ALS

Adam Staffaroni |  UCSF

Ashkan Vaziri Headshot

Digital Measurements of Motor and Voice Functions in FTD

Ashkan Vaziri | BioSensics

Treat FTD Fund

Anne-Marie Li-Kwai-Cheung

Wave Life Sciences: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Anne-Marie Li-Kwai-Cheung |  Wave Life Sciences

Dr. Simon Ducharme 041323

Clinical Trial of Nabilone for Neuropsychiatric Symptoms in Frontotemporal Dementia

Simon Ducharme, MD  |  McGill University

Paul Edison

Evaluating the effects of GLP-1 analog, oral semaglutide, as a treatment for sporadic behavioral variant frontotemporal dementia (bvFTD)

Paul Edison, MD  |  Imperial College London


Dopaminergic Therapy for Frontotemporal Dementia Patients

Giacomo Koch, PhD  |  Saint Lucia Foundation

Emiliano Santarnecchi, PhD-01

Non-Invasive Brain Stimulation for Gamma Induction and Cognitive Enhancement in FTD

Emiliano Santarnecchi, PhD  |  Harvard Medical School

Pilot Grants


Aberrant protein condensation as a driver of neuroinflammation in ALS/FTD

Steven Boeynaems | Baylor College of Medicine
April 2023


Defining the role of TBK1 loss-of-function in FTD

Daniel Mordes | UCSF
April 2023

Iordan - left - and postdoc

Social Network Neuromodulation in Behavioral Variant Frontotemporal Dementia

Alexandru Iordan | University of Michigan
April 2023

Alinka Fisher

Positive Behaviour Support (PBS) for individuals with frontotemporal dementia: increasing service and family capacity through a mentoring and training model

Alinka Fisher, PhD  |  Finders University
April 2022

Clinical Research Training Scholarship in FTD

Tanav Popli - Indiana University

Personalized HD-tDCS in Primary Progressive Aphasia

Tanav Popli | University of Michigan

Indira Garcia Cordero, PhD

Multimodal evidence of the role of Alzheimer’s disease pathology in corticobasal and progressive supranuclear palsy syndromes

Indira García Cordero, PhD  University of Toronto
$150,000 USD ($75,000/year)
Mentor: Carmela Tartaglia

Holloway Postdoctoral Fellowships


Targeting TDP-43 aggregation as therapeutics for ALS/FTD

Marc Shenouda | University of Toronto
July 2023


Virtual Reality Social Cognition Game for Preclinical Frontotemporal Dementia

Jackie Poos  | Erasmus Medical Center
July 2023

Eric Anderson, PhD

Investigating O-glycosylation modification in C9ORF72 FTD/ALS pathogenesis

Eric Anderson, PhD  |  University of Pittsburgh
$120,000 USD ($60,000/year)
Mentor: Udai Pandey, PhD

Suborno Jati, PhD

Deciphering the consequences of chromogranin A (CgA) depletion in tauopathy

Suborno Jati, PhD  |  University of California San Diego
$120,000 USD ($60,000/year)
Mentor: Renzo Mancuso

Julia Faura Llorens, PhD

Long-read transcriptomics in FTLD-TDP to aid in the identification of novel biomarkers and mechanistic insights

Julia Faura Llorens, PhD  |  Vlaams Instituut voor Biotechnologie (VIB)
$120,000 USD ($60,000/year)
Mentor: Rosa Rademakers

Indira Garcia Cordero, PhD

Indira García Cordero, PhD  University of Toronto

holloway postdoctoral fellowship winner daniel okobi image

Neuronal network dysfunction in neurodegenerative disease

Daniel Okobi, MD, PhD  |  University of California, Los Angeles
July 2021
$120,000 USD ($60,000/year)

Hijai Regina Shin-01

Dissecting the molecular consequences of C9orf72 loss in lysosomal homeostasis and ALS-FTD disease pathogenesis

Hijai Regina Shin, PhD  |  University of California, Berkeley
July 2021
$120,000 USD ($60,000/year)


Modulating TDP-43-dependent loss of STMN2 in FTD

Matthew Nolan, PhD  |  Massachusetts General Hospital
July 2021
$120,000 USD ($60,000/year)

Ming-Yuan Su, PhD

A structural approach to rescuing C9orf72 haploinsufficiency in ALS/FTD

Ming-Yuan Su, PhD  |  The Regents of the University of California
July 2019

Oriol Dols Icardo, PhD-01

Identification of an RNA-based biomarker for FTD

Oriol Dols Icardo, PhD  |  Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau
January 2020